vision changes on tirzepatide Weight-loss drugs like semaglutide and linked to rare loss condition Vision loss: GLP-1 drugs like

- Bc 2: Ly lng kem va

Mounjaro is approved by the Food and Drug Administration (FDA) to help manage blood sugar levels in people with type 2 diabetes

Phase 3 TRIUMPH-4 data showed a significant 23.7% mean weight loss at its highest dose over 68 weeks, with some individuals experiencing up to 28.7% reduction

Materials and methods Study design and ethical approval This randomized-controlled parallel study comprised 46 patients with active RA, currently receiving conventional DMARDs therapy (methotrexate, leflunomide, and hydroxychloroquine), who were randomly assigned into 2 equal groups

Accumulating evidence supports a possible reduction in risk of hepatocellular carcinoma as well as oesophageal, endometrial, prostate and ovarian cancers in those receiving GLP1RAs